Krupka, J. A., Moutsopoulos, I., Cutmore, N. H., Trethewey, C. S., Dayimu, A., Goodhew, R., Kaji, F., Raso-Barnett, L., Cheow, H., Elzubeir, L., Smith, J., Kamil, A., Barbara, R., Price, J., Elston, K., Kolodziejczyk, A., Tarantino, S., Mariscotti, F., Barry, P., Frost, S., Demiris, N., Thomas, M. G., Hassane, D., Munugalavadla, V., Nagumantry, S. K., Karanth, M. J., Ahearne, M., Shah, N., Fox, C. P., Anand, S., Hodson, D. J. (2026). Phased Variant–Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-01587